MANNKIND CORP

MNKD is the ticker symbol for MANNKIND CORP, a publicly traded US company.

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Key metrics include a return on equity of 28.1%, a debt-to-equity ratio of -13.58.

The company reports trailing twelve-month revenue of $90.17M and net loss of $16.62M.

FINOTAUR aggregates real-time and fundamental data on MNKD to help traders and investors make informed decisions. Track MNKD in your trading journal alongside other positions for a unified view of your portfolio.